OverviewSuggest Edit

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna, is used for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis, Translarna for mucopolysaccharidosis type I caused by nonsense mutation, Translarna for nonsense mutation aniridia, and Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy in collaboration with Spinal Muscular Atrophy Foundation.
TypePublic
Founded1998
HQSouth Plainfield, US
Websiteptcbio.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2018)511(+40%)
Job Openings3
Revenue (FY, 2018)$264.7 M(+37%)
Share Price (Jun 2019)$41 (-2%)

Key People/Management at PTC Therapeutics

Stuart Peltz

Stuart Peltz

CEO
Neil Almstead

Neil Almstead

Executive Vice President, Research, Pharmaceutical Operations & Technology
Mark Boulding

Mark Boulding

Executive Vice President and Chief Legal Officer
Mary Harmon

Mary Harmon

Senior Vice President, Corporate Relations
VMD Mark J. Pykett

VMD Mark J. Pykett

Chief Innovation Officer
Martin Rexroad

Martin Rexroad

Senior Vice President, Human Resources
Show more

PTC Therapeutics Office Locations

PTC Therapeutics has an office in South Plainfield
South Plainfield, US (HQ)
100 Corporate Ct
Show all (1)

PTC Therapeutics Financials and Metrics

PTC Therapeutics Revenue

PTC Therapeutics's revenue was reported to be $264.73 m in FY, 2018
USD

Revenue (Q1, 2019)

53.6m

EBIT (Q1, 2019)

(69.1m)

Market capitalization (10-Jun-2019)

2.4b

Closing stock price (10-Jun-2019)

41.0

Cash (31-Mar-2019)

201.1m

EV

2.4b
PTC Therapeutics's current market capitalization is $2.4 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

34.7m25.2m36.8m82.7m194.4m264.7m

Revenue growth, %

(27%)46%125%

General and administrative expense

25.2m82.1m97.1m121.3m153.5m

R&D expense

54.9m121.8m117.6m117.5m172.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

9.2m1.7m1.7m7.5m6.8m9.8m18.9m15.6m23.0m26.5m48.0m41.9m56.1m68.7m53.6m53.6m

Cost of goods sold

39.0k758.0k

Gross profit

26.5m47.2m

Gross profit Margin, %

100%98%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

15.4m49.7m58.0m58.3m111.8m169.5m

Accounts Receivable

11.1m24.9m40.4m67.9m

Inventories

1.6m3.9m5.9m4.7m10.8m16.1m

Current Assets

145.0m323.6m355.9m261.3m249.1m320.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

24.0m115.9m21.2m52.9m36.8m29.2m140.7m40.2m35.7m50.3m54.1m133.0m141.8m97.7m223.8m206.9m201.1m

Accounts Receivable

22.6m19.8m27.4m32.2m33.8m38.7m45.6m59.4m42.2m46.4m

Inventories

1.4m6.9m7.8m12.4m13.9m13.7m16.2m

Current Assets

160.1m249.4m230.3m213.5m289.8m264.6m384.2m326.4m297.4m280.6m240.7m227.0m221.3m242.0m375.6m313.3m479.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(51.6m)(93.8m)(170.4m)(142.1m)(79.0m)(128.1m)

Depreciation and Amortization

2.4m2.2m2.9m3.3m17.7m26.1m

Inventories

(760.5k)(2.3m)(2.1m)1.2m

Accounts Payable

5.2m16.9m17.0m4.3m24.0m43.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(33.7m)(14.1m)(39.2m)(66.5m)(37.9m)(76.3m)(119.5m)(41.2m)(80.1m)(115.3m)(29.1m)(46.5m)(80.3m)(19.3m)(28.8m)(79.8m)(72.1m)

Depreciation and Amortization

1.8m588.0k1.2m1.7m634.0k1.3m2.1m849.0k1.7m2.5m612.0k1.4m11.7m6.0m12.2m19.3m7.1m

Inventories

(1.3m)(3.4m)(3.3m)(334.0k)

Accounts Payable

3.2m(3.5m)(866.0k)4.3m(5.6m)(6.0m)2.9m(2.5m)(3.4m)2.1m(3.9m)12.5m11.8m(6.8m)2.2m18.6m(28.7m)
USDY, 2019

EV/EBIT

-34 x

EV/CFO

-55.5 x

Financial Leverage

2.5 x
Show all financial metrics

PTC Therapeutics Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Agilis BiotherapeuticsJuly 20, 2018$200 m

PTC Therapeutics Online and Social Media Presence

Embed Graph

PTC Therapeutics News and Updates

PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

SOUTH PLAINFIELD, N.J., June 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to include patients ...

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J., March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company 39th Annual Health Care Conference Monday, March 11th at 11:20 a.m. ET Barclays Global...

PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares

SOUTH PLAINFIELD, N.J., Feb. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the sole underwriter of its previously announced public offering of 6,720,000 shares of its common stock, which closed on January 25, 2019, has partially exercised its option...

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results

SOUTH PLAINFIELD, N.J., Oct. 22, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2018 financial results and provide an update on the company's business and outlook on Monday,...

PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation

SOUTH PLAINFIELD, N.J., Oct. 6, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced preliminary data from the first international drug registry for Duchenne patients receiving Translarna™ (ataluren), underscoring the long-term clinical benefit of Translarna when...

PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics

SOUTH PLAINFIELD, N.J., Aug. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that it has successfully completed the acquisition of Agilis Biotherapeutics, Inc., a private biotechnology company focused on the advancement of innovative gene therapy programs...
Show more

PTC Therapeutics Blogs

PTC to Expand Product Portfolio in Latin America with WAYLIVRA™

WAYLIVRA, the first and only therapy for the treatment of familial chylomicronemia syndrome (FCS), has received a positive opinion from the CHMP SOUTH PLAINFIELD, N.J. , March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics ,

PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update

SOUTH PLAINFIELD, N.J. , Feb. 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2018 . "We are proud to be in the strong position of having a growing revenue base

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results Content Import Thu, 02/14/2019 - 08:08 PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results Feb 14, 2019 Th…

PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy

PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy Content Import Wed, 02/13/2019 - 08:06 PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy Feb 13, 2019 This release…

PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders

- $500,000 funding to improve Duchenne muscular dystrophy diagnosis and screening in 2019 - SOUTH PLAINFIELD, N.J. , Jan. 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today launched PRIORITY, an annual funding program for innovative research.

PTC Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH PLAINFIELD, N.J. , Jan. 22, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $200 million of shares of its common stock. All of the shares in the offering are to be sold by PTC.
Show more

PTC Therapeutics Frequently Asked Questions

  • When was PTC Therapeutics founded?

    PTC Therapeutics was founded in 1998.

  • Who are PTC Therapeutics key executives?

    PTC Therapeutics's key executives are Stuart Peltz, Neil Almstead and Mark Boulding.

  • How many employees does PTC Therapeutics have?

    PTC Therapeutics has 511 employees.

  • What is PTC Therapeutics revenue?

    Latest PTC Therapeutics annual revenue is $264.7 m.

  • What is PTC Therapeutics revenue per employee?

    Latest PTC Therapeutics revenue per employee is $518.1 k.

  • Who are PTC Therapeutics competitors?

    Competitors of PTC Therapeutics include Inovio Pharmaceuticals, Alimera Sciences and Marinus Pharmaceuticals.

  • Where is PTC Therapeutics headquarters?

    PTC Therapeutics headquarters is located at 100 Corporate Ct, South Plainfield.

  • Where are PTC Therapeutics offices?

    PTC Therapeutics has an office in South Plainfield.

  • How many offices does PTC Therapeutics have?

    PTC Therapeutics has 1 office.